Login / Signup

IL-7 germline variant: setting the stage for immune-related adverse events.

Hussein IssaouiJean-Ehrland Ricci
Published in: Molecular oncology (2023)
Treatment with immune checkpoint inhibitors (ICIs) is frequently associated with immune-related adverse events (irAEs). A new study identified an interleukin 7 (IL-7) allelic variant-rs16906115-as a major risk factor for the development of ICI-associated irAEs. This association is of great significance as it indicates that germline genetic variants influence the occurrence of irAEs, thus opening a new avenue for identifying high-risk patients to enable better management of ICI therapy and associated irAEs.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • dna repair
  • risk assessment
  • prognostic factors
  • stem cells
  • oxidative stress
  • mesenchymal stem cells
  • dna damage
  • drug induced